Divergence Labs Preprint Claims Claude-Designed Antibody Removes Receptor-Bound IgE

Divergence Labs has published a preprint, dated 29 October 2026, claiming its antibody, designed through an agentic (multistep, AI-driven) computational campaign run with Claude, physically removes IgE already bound to the FcεRI receptor. The company contrasts this with Omalizumab (Xolair), which neutralizes circulating IgE. The preprint is the company's own technical account, aimed at food allergy.